Salicin inhibits AGE-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes: therapeutic potential in osteoarthritis
Authors:
Open Access
- 3 April 2019
- journal article
- research article
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 47 (1) , 1043-1049
Abstract
Osteoarthritis (OA) is a major age-related disease, which may be caused by the accumulation of advanced glycation end-products (AGEs). Excessive degradation of type II collagen and aggrecan by matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS) induced by AGEs is a pivotal event in the pathogenesis of osteoarthritis. In addition, activation of the nuclear factor-κB (NF-κB) pathway induces the expression of a cascade of proinflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor-α (TNF-α). In the present study, we investigated the effects of salicin, one of the main constituents of aspirin and a derivative of Alangium chinense, on AGE-induced degradation of the articular extracellular matrix in SW1353 human chondrocytes. Our findings reveal a novel beneficial role of salicin in rescuing degradation of type II collagen and aggrecan, reducing oxidative stress, attenuating expression of proinflammatory cytokines, and inhibiting activation of the NF-κB proinflammatory signaling pathway in chondrocytes stimulated with AGEs. Salicin may thus have potential as a safe and effective therapy against the development and progression of OA.Keywords
This publication has 28 references indexed in Scilit:
- TNF-α and IL-1β Promote a Disintegrin-like and Metalloprotease with Thrombospondin Type I Motif-5-mediated Aggrecan Degradation through Syndecan-4 in Intervertebral DiscJournal of Biological Chemistry, 2011
- ADAMTS-4 and ADAMTS-5: Key enzymes in osteoarthritisJournal of Cellular Biochemistry, 2011
- Inflammation in osteoarthritisCurrent Opinion in Rheumatology, 2011
- Role of proinflammatory cytokines in the pathophysiology of osteoarthritisNature Reviews Rheumatology, 2010
- High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic diseaseArthritis Research & Therapy, 2008
- Advanced glycation end products increases matrix metalloproteinase‐1, ‐3, and ‐13, and TNF‐α in human osteoarthritic chondrocytesFEBS Letters, 2007
- HMGB1, a novel inflammatory cytokineClinica Chimica Acta, 2007
- NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritisOsteoarthritis and Cartilage, 2006
- Protein carbonylation, cellular dysfunction, and disease progressionJournal of Cellular and Molecular Medicine, 2006
- Small-molecule inhibitors of NF-κB for the treatment of inflammatory joint diseaseCurrent Opinion in Pharmacology, 2002